Transcription of Novartis Fourth Quarter and Full Year 2021
{{id}} {{{paragraph}}}
Example: bachelor of science
Novartis Fourth Quarter and Full Year 2021
Novartis Fourth Quarter and full year 2021. Condensed financial report . supplementary data Novartis Global Communications Novartis Fourth Quarter and full year 2021. Condensed Financial Report . Supplementary Data INDEX Page GROUP AND DIVISIONAL OPERATING PERFORMANCE. Group 3. Innovative Medicines 7. Sandoz 14. CASH FLOW AND GROUP BALANCE SHEET 16. INNOVATION REVIEW 19. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS. Consolidated income statements 22. Consolidated statements of comprehensive income 24. Consolidated balance sheets 25. Consolidated statements of changes in equity 26. Consolidated statements of cash flows 29. Notes to condensed consolidated financial statements, including update on legal proceedings 31. SUPPLEMENTARY INFORMATION 50. CORE RESULTS. Reconciliation from IFRS results to core results 52. Group 54. Innovative Medicines 56. Sandoz 57. Corporate 58. ADDITIONAL INFORMATION. Income from associated companies 58. Condensed consolidated changes in net debt / Share information 59.
Nov 03, 2021 · Free cash flow amounted to USD 3.0 billion (–9% USD), compared to USD 3.3 billion in the prior year quarter. Higher operating income adjusted for non-cash items and other adjustments was more than offset by higher income taxes paid and lower divestment proceeds. Full year Net sales Net sales were USD 51.6 billion (+6%, +4% cc) in the full year.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: